Phase II
Primary analysis of L-MIND trial of tafasitamab (MOR208) plus lenalidomide in relapsed or refractory (r/r) DLBCL confirms overall strong data reported previously from this trial
MorphoSys AG today announced results from the primary analysis (cut-off date November 30, 2018) of the ongoing single-arm phase 2 clinical trial known as L-MIND.
“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.
Yamo Pharmaceuticals, LLC announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD.
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
PRESS RELEASES